The treatment of advanced gastrointestinal stromal tumors (GIST) has improved in recent years with the introduction of tyrosine kinase inhibitors (......READ MORE
by Suzanne George, MD; Richard F. Riedel, MD; and Jonathan C. Trent, MD, PhD
In the current paradigm, non–wild-type metastatic gastrointestinal stromal tumors (GIST) are generally treated in a sequential fashion with imatini......READ MORE
by Suzanne George, MD; Richard F. Riedel, MD; and Jonathan C. Trent, MD, PhD
The management of side effects from tyrosine kinase inhibitor (TKI) therapy often requires a multidisciplinary approach, with aggressive supportive......READ MORE
patient care perspectives by Michael C. Heinrich, MD
The risk of recurrence, growth, and spread of gastrointestinal stromal tumors (GIST) after surgery relates to key variables such as the size, locat......READ MORE
Newer targets and combinations are being explored to help bridge the gap for patients with advanced gastrointestinal stromal tumors (GIST). Our fea......READ MORE
Late-line tyrosine kinase inhibitor (TKI) dose escalation may benefit a subset of patients with gastrointestinal stromal tumors (GIST), allowing fo......READ MORE
